| DC11937 |
PF 05180999
Featured
|
PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM. |
|
| DC7201 |
PF-2545920(MP-10)
Featured
|
PF-2545920 a highly selective and potent PDE10A inhibitor with an IC50 of 0.37 nM. |
|
| DC7247 |
PF-8380
Featured
|
PF-8380 is a potent and specofic autotaxin inhibitor with an IC50 value of 2.8 nM. |
|
| DC4146 |
Roflumilast
Featured
|
Roflumilast (Daxas) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM. |
|
| DC11671 |
RPL-554 |
RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively. |
|
| DC8048 |
SEP-0372814
Featured
|
SEP-0372814 is a potent PDE10 inhibitor. |
|
| DC9779 |
Sildenafil citrate
Featured
|
Sildenafil citrate, one of the selective phosphodiesterase-5 (PDE5) inhibitors(IC50= 5.22 nM), is considered the best treatment for erectile dysfunction. |
|
| DC7298 |
MY-5445 |
Specific inhibitor of cyclic GMP phosphodiesterase, selective for PDE5 (IC50 = 0.5 μM). |
|
| DC5901 |
Tadalafil
Featured
|
Tadalafil is a potent and selective inhibitor of Phosphodiesterase-5 (PDE5) This compound prevents the breakdown of phosphodiesterases, many of which are used as secondary messengers. By preventing the breakdown of these messenger molecules, tadalafil can |
|
| DC7945 |
TAK-063
Featured
|
TAK-063 is a highly potent, selective and orally active PDE10A inhibitor with IC50 of 0.30 nM; >15000-fold selectivity over other PDEs. |
|
| DC11661 |
BAY 73-6691 |
BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. |
|
| DC4133 |
Udenafil |
Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED) |
|
| DC9182 |
Vardenafil hydrochloride trihydrate
Featured
|
Vardenafil is a PDE5 inhibitor used for treating erectile dysfunction. |
|
| DC9847 |
Vesnarinone(OPC8212)
Featured
|
Vesnarinone is a quinolinone derivative, and its pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, increases in calcium flux and decreases in potassium flux. |
|
| DC28354 |
(E/Z)HA-155
Featured
|
(E/Z)HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM. |
|
| DC28378 |
THPP-1
Featured
|
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species. |
|
| DC28708 |
ATX inhibitor 5 |
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 has anti-hepatofibrosis effect, and reduces CCl4-induced hepatic fibrosis level prominently. |
|
| DC28759 |
Autotaxin-IN-3 |
Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC50 of 2.4 nM, compound 33, sourced from patent WO2018212534A1. |
|
| DC28761 |
Autotaxin-IN-4 |
Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis. |
|
| DC28762 |
Autotaxin-IN-5 |
Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis. |
|
| DC29002 |
Siguazodan |
Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM. |
|
| DC29034 |
ent-Tadalafil |
ent-Tadalafil (ent-IC-351), compound (6S,12aS), is a inactive cis-enantiomer of compound (6R,12aS). compound (6R,12aS) is a potent PDE5 inhibitor with an IC50 of 0.090 μM, while ent-Tadalafil is inactive at concentrations up to 10 µM. |
|
| DC40058 |
GSK356278 |
GSK356278 is a potent, selective, orally bioavailable and brain-penetrant inhibitor of phosphodiesterase 4 (PDE4), with pIC50s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE4D, respectively. GSK356278 has anti-inflammatory activity, and exhibits anxiolytic and cognition-enhancing effects. |
|
| DC40284 |
Kuraridine |
Kuraridine is a prenylated flavonol extract from the roots of?Sophora flavescens. Kuraridine an inhibitory effect on cGMP specific phosphodiesterase type 5?(PDE5) and has an IC50 of 0.64 μM. |
|
| DC40378 |
MR-L2
Featured
|
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM. |
|
| DC40484 |
Homo Sildenafil |
Homo Sildenafil, an analog of Sildenafil, acts as a phosphodiesterase inhibitor. |
|
| DC40895 |
BRD9500 |
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC50s of 10 and 27 nM for PDE3A and PDE3B, respectively. Antitumor activity. |
|
| DC40977 |
DSR-141562
Featured
|
DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia. |
|
| DC41053 |
Acetildenafil |
Acetildenafil is a derivative of the phosphodiesterase 5 (PDE5) inhibitor Sildenafil. |
|
| DC41313 |
3-O-Methylquercetin |
3-O-Methylquercetin (3-MQ), a main constituent of Rhamnus nakaharai, inhibits total cAMP and cGMP-phosphodiesterase (PDE) of guinea pig trachealis. 3-O-Methylquercetin (3-MQ) exhibits IC50 values of 31.9 μM， 86.9 μM， 18.6 μM and 1.6 μM for PDE1, PDE5, PDE2 and PDE4, respectively. |
|
